At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MNOV MediciNova
Trading 12-23 10:09:05 EST
2.10
-0.07
-3.23%
High2.15
Low2.09
Vol20.40K
Open2.15
D1 Closing2.17
Amplitude2.77%
Mkt Cap103.00M
Tradable Cap88.37M
Total Shares49.05M
T/O43.68K
T/O Rate0.05%
Tradable Shares42.08M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
MNOV: Encouraging Interim Analysis for Phase 2b/3 ALS Trial…
Medicinova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of Mn-166 (Ibudilast) in ALS (Combat-ALS Clinical Trial) at the 35TH International Symposium on ALS/Mnd
MediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MND
Medicinova Receives Notice of Allowance From United States Patent and Trademark Office for New Patent Covering Mn-001 for Triglyceride Synthesis in the Liver
MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.